Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke

Status Recruiting

Clinical Trial Summary

This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.

Clinical Trial Description

Preclinical studies support that HBOT augments several adaptive mechanisms following ischemic stroke, including neuroplasticity, cerebral angiogenesis, and regeneration of nerve fibers. The earlier the treatment, the greater potential for a therapeutic effect. However, logistical issues and safety concerns have prevented application of HBOT in the hyperacute window, particularly when coupled with recanalization therapy as the risk of hemorrhagic conversion is highest, monitoring intervals are short, and the natural history is being altered by another treatment. By enrolling patients who are in the subacute phase of stroke who are admitted to an inpatient rehab facility, the risk of HBOT is lower, monitoring intervals are longer, and the selected population has newly acquired and targetable stroke-related disability. Further, the patients are in a supervised setting and available for daily one-hour treatments without disrupting their intensive multidisciplinary rehab plan thereby minimizing nonadherence to daily treatments. Neuroimaging supports that injured, but not dead, brain cells can persist for months after an ischemic event. Hypoxia mediates cellular activity and death through multiple mechanisms. Ongoing decrease in oxygenation to the damaged area due to impaired blood flow works against cellular repair, recovery, and development of new synaptic connections. Increasing oxygen availability has been considered as an obvious treatment for stroke. HBOT has the potential to facilitate the recovery of injured or inactive neurons through increased blood flow and oxygen delivery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06148285
Study type	Interventional
Source	LCMC Health
Contact	Lawrence Matarutse
Phone	504-962-6419
Email	Lawrence.Matarutse@lcmchealth.org
Status	Recruiting
Phase	N/A
Start date	May 24, 2022
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06113848` - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy	Phase 3
Completed	`NCT04069546` - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency	N/A
Active, not recruiting	`NCT05700097` - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy	Phase 2
Recruiting	`NCT06058130` - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis	N/A
Recruiting	`NCT04415164` - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke	Phase 4
Recruiting	`NCT05363397` - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke	Phase 2
Completed	`NCT05429658` - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System	N/A
Recruiting	`NCT05390580` - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct	N/A
Enrolling by invitation	`NCT05515393` - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke	Phase 2
Active, not recruiting	`NCT05070260` - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo	Phase 2/Phase 3
Terminated	`NCT05547412` - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed	`NCT03366818` - New Stent Retriever, VERSI System for AIS	N/A
Not yet recruiting	`NCT05293080` - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE	Phase 3
Not yet recruiting	`NCT06437431` - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy	Phase 2/Phase 3
Not yet recruiting	`NCT06040476` - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)	Phase 2
Completed	`NCT02223273` - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)	N/A
Completed	`NCT02586233` - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke	Phase 1/Phase 2
Terminated	`NCT01694381` - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor	Early Phase 1
Not yet recruiting	`NCT01594190` - Physical Activity Immediately After Acute Cerebral Ischemia	N/A
Completed	`NCT01120301` - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms